FDA declines leucovorin for autism
Digest more
Researchers are reacting to the FDA's decision not to approve the prescription drug leucovorin for the treatment of autism.
The FDA announced a new approved use for the drug leucovorin, which Trump has touted as a treatment for autism. But the approval is for cerebral folate deficiency.
A new U.S. autism research panel is examining potential causes of autism, sparking debate over science, policy, and the future of autism research.
The FDA has expanded its approval of leucovorin calcium tablets to treat cerebral folate deficiency in patients with a folate receptor 1 gene variant, according to a press release from the agency. Calling leucovorin the first approved treatment for this disease,
Founders of the new Independent Autism Coordinating Committee say they will act as an alternative body to a federal advisory group under RFK Jr.
The drug leucovorin was touted by the Trump administration in September as a potential treatment for thousands of children with autism. Now, some parents and guardians of children with autism say they feel abandoned by the US Food and Drug Administration’s new stance on leucovorin.